Talha Badar, Hematologist/Oncologist at Mayo Clinic, shared a post on X/Twitter:

“Efficacy of autologous and allogeneic hematopoietic cell transplantation in Acute Promyelocytic Leukemia (APL): systemic review and meta-analysis. A big shout out to Razan Mohty for leading this effort!

Congratulation to all co-authors at Mayo Clinic, Florida.

• Highlights: 10% of patients experience disease relapse following front-line therapy.
• Pooled EFS rates for autologous and allogeneic hematopoietic cell transplantation
  are 71% and 54%, respectively.
• Pooled OS rates for autologous and allogeneic hematopoietic cell transplantation
  are 82% and 58%, respectively.
• There is a higher risk of pooled NRM rate with an allogeneic hematopoietic cell transplantation (29% vs. 5%).”

Additional information.
Source: Talha Badar/X